EMA validates MAA for Prolia and Xgeva (denosumab) biosimilar candidate HLX14
The European Medicines Agency (EMA) has validated the marketing authorisation applications (MAAs) for HLX14, an investigational biosimilar to Prolia and Xgeva (denosumab). This announcement was made by Shanghai Henlius Biotech and Organon. Denosumab has …